Menu Search
Equities

DocMorris AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ZRE:MUN

DocMorris AG

Actions
  • Price (EUR)6.44
  • Today's Change-0.085 / -1.30%
  • Shares traded2.00k
  • 1 Year change--
  • Beta1.3724
Data delayed at least 15 minutes, as of Feb 06 2026 08:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

DocMorris AG, formerly Zur Rose Group AG, is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. DocMorris operates at the healthcare, technology and e-commerce, with a primary focus on customer-centric digital healthcare and improving medication efficacy. core business is online pharmacy. In addition to prescription medicines (Rx), assortment features over-the-counter (OTC) and consumer health as well as beauty and personal care (BPC) products. Private labels, including nutritional supplements, painkillers, first-aid products and other OTC medicines. The Company's operates under brands such as PromoFarma, DoctiPharma, Apotal, Medpex and Teleclinic, among others

  • Revenue in CHF (TTM)1.06bn
  • Net income in CHF-120.87m
  • Incorporated1993
  • Employees1.45k
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.